about
Mitochondrial ADCK3 employs an atypical protein kinase-like fold to enable coenzyme Q biosynthesisFrom integrative genomics to therapeutic targetsCerebellar Ataxia and Coenzyme Q Deficiency through Loss of Unorthodox Kinase ActivityStructure-Based Design of Orally Bioavailable 1 H -Pyrrolo[3,2- c ]pyridine Inhibitors of Mitotic Kinase Monopolar Spindle 1 (MPS1)SF3B1 mutations constitute a novel therapeutic target in breast cancer.CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.Drugging the addict: non-oncogene addiction as a target for cancer therapyCoexpression and coregulation analysis of time-series gene expression data in estrogen-induced breast cancer cellValidation of the Cancer BioChip System as a 3D siRNA screening tool for breast cancer targetsCharacterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast.Characterisation of CCT271850, a selective, oral and potent MPS1 inhibitor, used to directly measure in vivo MPS1 inhibition vs therapeutic efficacyUse of RNAi screens to uncover resistance mechanisms in cancer cells and identify synthetic lethal interactions.Polo-like kinase 4 inhibition: a strategy for cancer therapy?Molecular characterisation of cell line models for triple-negative breast cancers.ATARiS: computational quantification of gene suppression phenotypes from multisample RNAi screensIdentification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers.Luteolin is a novel p90 ribosomal S6 kinase (RSK) inhibitor that suppresses Notch4 signaling by blocking the activation of Y-box binding protein-1 (YB-1)TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer.Pharmacological profiling of kinase dependency in cell lines across triple-negative breast cancer subtypes.Profiling the tyrosine phosphoproteome of different mouse mammary tumour models reveals distinct, model-specific signalling networks and conserved oncogenic pathways.YB-1 transforms human mammary epithelial cells through chromatin remodeling leading to the development of basal-like breast cancerIntrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial.The oncogenic STP axis promotes triple-negative breast cancer via degradation of the REST tumor suppressorEnzyme kinetics and distinct modulation of the protein kinase N family of kinases by lipid activators and small molecule inhibitors.Inhibition of RSK with the novel small-molecule inhibitor LJI308 overcomes chemoresistance by eliminating cancer stem cells.HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancersToward personalized cancer nanomedicine - past, present, and future.Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines.Whole-genome duplication increases tumor cell sensitivity to MPS1 inhibition.Preclinical validation of a novel compound targeting p70S6 kinase in breast cancer.Quantitative high-throughput efficacy profiling of approved oncology drugs in inflammatory breast cancer models of acquired drug resistance and re-sensitization.Synthetic lethal targeting of PTEN-deficient cancer cells using selective disruption of polynucleotide kinase/phosphataseA negative genetic interaction map in isogenic cancer cell lines reveals cancer cell vulnerabilitiesRSK-mediated down-regulation of PDCD4 is required for proliferation, survival, and migration in a model of triple-negative breast cancer.Interactions between FGFR2 and RSK2-implications for breast cancer prognosis.ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A.Loss of AXIN1 drives acquired resistance to WNT pathway blockade in colorectal cancer cells carrying RSPO3 fusionsAn siRNA screen identifies the GNAS locus as a driver in 20q amplified breast cancer.Reviewing the somatic genetics of melanoma: from current to future analytical approaches.Discovery of small molecule cancer drugs: successes, challenges and opportunities.
P2860
Q24309318-D03CC91C-7465-4E03-9703-86B1199D3F9EQ26862726-471D7398-D7BC-4EF2-887B-BE1004060739Q27644667-A57F4860-0561-46C8-85A3-072974D46784Q27680652-FDDC241B-D50C-479D-A12F-D07588943434Q27853097-F660DD07-B01E-4D3B-92D0-352E5384F844Q27853338-5D82211E-C07B-4631-AC05-D3A0A1BCBBA8Q28079559-F129F38E-63C9-44AE-8D3D-D514A66927A0Q30605508-816A4906-0288-4D99-BF99-BC9DEF6EC780Q31103913-86048427-F9DB-42A9-86CB-E9B2318ED943Q33579776-D81DB763-ADD9-4114-A015-ECF795108596Q33639719-D584D673-E2C0-4611-BC55-07832952BEFEQ33651791-72D2738E-916D-4771-9EFE-0276FFAE1CE4Q34103564-9E04C0B4-5081-4E8E-89F9-C8AC8F5EA650Q34476551-DCB3B39B-0BED-4D57-8C3D-0324C07EF601Q34523383-76AAF300-0A4A-4008-8477-134CC01D2D31Q34615545-F5CE5B4F-E4A0-4E52-BAB5-074D68865453Q34675192-F8D73333-84A3-4F20-88A8-DC7D7364C0BCQ34735167-494E3E46-C69F-4897-A1DD-CFF9D33B5CA1Q34978420-B9DCA71A-9B95-48D0-8DAE-10E163E50F6BQ35000261-C985F27A-7C99-4FE1-808E-A0EF6B9ED25AQ35063920-C5793A0D-C54E-4429-A1C1-06A0C201D847Q35419840-B1249004-58FC-4D68-9927-5C352362442CQ35592084-384D4284-E4AF-4739-B8F4-323E59862CD5Q36213543-66780EBA-D5CA-433D-96A0-089350A96FFDQ36299754-ED877E0F-0716-4272-826D-50DB0FB36B71Q36354259-03AF629D-CFC1-4C86-9E6B-034B56E70F39Q36472802-62CD1342-C06A-4EDD-80F2-D286A9BC1975Q36713548-C76BE2D4-9D63-42E6-8A22-5602F82F5FBBQ36729558-D560F6E4-7B90-4171-ADFE-22D200F5D49AQ37062488-3ED86DEF-0D2B-44A7-A761-FCF7C2893D0CQ37149249-B6326ED0-F118-4782-AF9F-CD64C70B7A34Q37223362-E04BCD1F-8563-48F4-BD96-56E7263F5007Q37279495-F1683C72-5AE5-4E43-B8DC-D569B403E9ADQ37317329-DF346555-66EF-4891-8967-E8F6F6BDA510Q37396056-3D7ACD3B-00DE-423E-8548-5B443605455BQ37508792-8E65EFCB-05E5-4834-9D7F-0EC0210305A7Q37672680-E35DCF7E-D793-4310-84B8-787162B3F1BFQ37676107-D03BE5CC-FA7B-4FBF-B773-D8D06F4DF2D3Q37976140-60F22AD2-7747-4240-839F-2E4EDD1B4C75Q37996113-0EAB3CA4-68E0-4119-978F-3B4B34275917
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Functional viability profiles of breast cancer.
@ast
Functional viability profiles of breast cancer.
@en
type
label
Functional viability profiles of breast cancer.
@ast
Functional viability profiles of breast cancer.
@en
prefLabel
Functional viability profiles of breast cancer.
@ast
Functional viability profiles of breast cancer.
@en
P2093
P2860
P50
P1433
P1476
Functional viability profiles of breast cancer.
@en
P2093
Alan Mackay
Amar S Ahmad
Ana M Mendes-Pereira
Daniel Wetterskog
David Sims
Ilirjana Bajrami
Jessica R Frankum
Kai-Keen Shiu
Konstantine J Dedes
Maria Antonietta Cerone
P2860
P304
P356
10.1158/2159-8290.CD-11-0107
P577
2011-08-02T00:00:00Z